Five-Year Fracture Outcomes with Zoledronate in Postmenopausal Osteoporotic Women with and without Diabetes
Hormone and Metabolic Research · 01.03.2026 · 58 (03) · 103-113
DOI: 10.1055/a-2812-1745 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.03.2026. Verfasst von Somdatta Giri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. Hauptthemen laut MEDLINE: Zoledronic Acid, Diabetes Mellitus, Type 2, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: The Endocrine Society of Tamilnadu, Jawaharlal Institute Of Postgraduate Medical Education and Research.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Zoledronate is most effective when bone turnover is elevated, as in postmenopausal women. Individuals with type 2 diabetes mellitus show lesser bone mineral density gains compared to non-diabetes mellitus individuals with zoledronate, and fractures often occur despite preserved bone mineral density. It is unclear whether zoledronate reduces fracture risks in type 2 diabetes mellitus. This study aimed to evaluate skeletal outcomes, including fracture incidence, over 5 years in postmenopausal osteoporotic women with and without type 2 diabetes mellitus. This prospective cohort included postmenopausal women with bone mineral density T-scores of≤–2.5 at the lumbar spine, femoral neck, or hip. Participants were classified as type 2 diabetes mellitus or non-diabetes mellitus. All received annual zoledronate (4 mg), daily calcium (1000 mg), and cholecalciferol (500 IU), with standardized fall-prevention measures. Fracture history was recorded at follow-up visits, and annual spine radiographs were performed to detect morphometric vertebral fractures. Women completing≥5 years of follow up were included in the final analysis. The primary end point was fracture incidence; secondary end points were changes in bone mineral density and bone turnover markers. Of 221 women enrolled, 150 completed 5 years (63 type 2 diabetes mellitus and 87 non-diabetic mellitus; median age 59 y). The baseline bone mineral density was similar, but bone turnover markers were lower in type 2 diabetes mellitus. At a minimum of 60 months follow up, 20 new fractures occurred in 15 women: 8 (12.7%) with type 2 diabetes mellitus and 7 (8.0%) without. The relative risk (RR) was 1.58 (95% confidence interval: 0.60–4.13; p=0.2). Both groups showed comparable bone mineral density improvements. Despite differences in baseline bone turnover, fracture incidence did not differ significantly between postmenopausal women with and without type 2 diabetes mellitus treated with annual zoledronate over a 5-year follow-up. However, the low number of fracture events and wide confidence intervals limit definitive inference.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
- Radio Diagnosis, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
- Endocrinology, Vijay Diabetes, Thyroid and Endocrine Clinic, Puducherry, India.
ORCID-Profile: Somdatta Giri, Dukhabandhu Naik
Förderung
- The Endocrine Society of Tamilnadu
- Jawaharlal Institute Of Postgraduate Medical Education and Research
Zitieren
APA
Giri, S., Ramkumar, G., Sahoo, J., Kamalanathan, S., Naik, D., Reddy, S. V. B., Merugu, C., Durgia, H., Venkatesh, S., Suryadevara, V., & Mondal, S. A. (2026). Five-Year Fracture Outcomes with Zoledronate in Postmenopausal Osteoporotic Women with and without Diabetes. Hormone and Metabolic Research, 58(03), 103-113. https://doi.org/10.1055/a-2812-1745
Vancouver
Giri S, Ramkumar G, Sahoo J, Kamalanathan S, Naik D, Reddy SVB, et al. Five-Year Fracture Outcomes with Zoledronate in Postmenopausal Osteoporotic Women with and without Diabetes. Hormone and Metabolic Research. 2026;58(03):103-113. doi:10.1055/a-2812-1745
BibTeX
@article{Giri2026,
author = {Giri, Somdatta and Ramkumar, Govindarajalou and Sahoo, Jayaprakash and Kamalanathan, Sadishkumar and Naik, Dukhabandhu and Reddy, Sagili Vijaya Bhaskar and Merugu, Chandhana and Durgia, Harsh and Venkatesh, Sunthoju and Suryadevara, Varun and Mondal, Samim Ali},
title = {Five-Year Fracture Outcomes with Zoledronate in Postmenopausal Osteoporotic Women with and without Diabetes},
journal = {Hormone and Metabolic Research},
year = {2026},
volume = {58},
number = {03},
pages = {103--113},
doi = {10.1055/a-2812-1745}
}
EUVIMED